Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of t helper-type cytokine response induced by acellular pertussis vaccine

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 1, 2006, Pages 97-104

  Ausiello, C M ^a   Palazzo, R ^a   Spensieri, F ^a   Urbani, F ^a   Massari, M ^a   Triebel, F ^b   Benagiano, M ^c   D'Elios, M M ^c   Del Prete, G ^c   Cassone, A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acellular pertussis vaccines; Bordetella pertussis; Lymphocyte activation gene 3 (CD223); Soluble CD30; T helper (Th) 1 and Th2

Indexed keywords

BIOLOGICAL MARKER; CD30 ANTIGEN; DIPHTHERIA TETANUS VACCINE; PERTUSSIS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; GENE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION GENE 3; PERTUSSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TH1 CELL; TH2 CELL; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIGENS, CD; ANTIGENS, CD30; BIOLOGICAL MARKERS; CHILD; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; IMMUNITY, CELLULAR; PERTUSSIS VACCINE; TH1 CELLS; TH2 CELLS; VACCINES, ACELLULAR;

EID: 33646268790     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mills K.H. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655.
2. Cassone A., C.M. Ausiello, F. Urbani, R. Lande, M. Giuliano, A. La Sala, A. Piscitelli and S. Salmaso. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch. Pediatr. Adolesc. Med. 151:283.
3. Ausiello C.M., F. Urbani, A. la Sala, R. Lande and A. Cassone. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:2168.
4. Ryan M., G. Murphy, L. Gothefors, L. Nilsson, J. Storsaeter and K.H. Mills. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175:1246.
5. Miller E., L.A. Ashworth, K. Redhead, C. Thornton, P.A. Waight and T. Coleman. 1997. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15:51.
6. He Q., N.N. Iran Minh, K. Edelman, M.K. Viljanen, H. Arvilommi and J. Mertsola. 1998. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infect. Immun. 66:3796.
7. Ryan M., G. Murphy, E. Ryan, L. Nilsson, F. Shackley, L. Gothefors, K. Oymar, E. Miller, J. Storsaeter and K. H. Mills. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1.
8. Ausiello C.M., R. Lande, F. Urbani, B. Di Carlo, P. Stefanelli, S. Salmaso, P. Mastrantonio and A. Cassone. 2000. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181:1989.
9. Zepp F., M. Knuf, P. Habermehl, J.H. Schmitt, C. Rebsch, P. Schmidtke, R. Clemens and M. Slaoui. 1996. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect. Immun. 64:4078.
10. Mascart F., V. Verscheure, A. Malfroot, M. Hainaut, D. Pierard, S. Temerman, A. Peltier, A.S. Debrie, J. Levy, G. Del Giudice and C. Locht. 2003. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J. Immunol. 170:1504.
11. Storsaeter J., H.O. Hallander, L. Gustafsson and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907.
12. Cherry J.D., J. Gornbein, U. Heininger and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901.
13. Cherry J.D. and P. Olin. 1999. The science and fiction of pertussis vaccines. Pediatrics 104:1381.
14. Greco D., S. Salmaso, P. Mastrantonio, M. Giuliano, A.E. Tozzi, A. Anemona, M.L. Ciofi degli Atti, A. Giammanco, P. Panei, W.C. Blackwelder, D.L. Klein and S.G. Wassilak. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334:341.
15. Olin P., F. Rasmussen, L. Gustafsson, H.O. Hallander and H. Heijbel. 1997. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350:1569.
16. Simondon F., M.P. Preziosi, A. Yam, C.T. Kane, L. Chabirand, I. Iteman, G. Sanden, S. Mboup, A. Hoffenbach, K. Knudsen, N. Guiso, S. Wassilak and M. Cadoz. 1997. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15:1606.
17. Cherry J.D. 1997. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16(S):90.
18. Giuliano M., P. Mastrantonio, A. Giammanco, A. Piscitelli, S. Salmaso and S. G. Wassilak. 1998. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132:983.
19. Romagnani S. 1997. The Th1/Th2 paradigm. Immunol. Today 18:263.
20. Perussia B. and M.J. Loza. 2003. Linear "2-0-1" lymphocyte development: hypotheses on cellular bases for immunity. Trends Immunol. 24:235.
21. Ausiello C.M., R. Lande, A. la Sala, F. Urbani and A. Cassone. 1998. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178:466.
22. Ausiello C.M., R. Lande, F. Urbani, A. la Sala, P. Stefanelli, S. Salmaso, P. Mastrantonio and A. Cassone. 1999. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67:4064.
23. Fedele G., P. Stefanelli, F. Spensieri, C. Fazio, P. Mastrantonio and C.M. Ausiello. 2005. Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression. Infect. Immun. 73:1590.
24. Annunziato F., R. Manetti, I. Tomasevic, M.G. Guidizi, R. Biagiotti, V. Gianno, P. Germano, C. Mavilia, E. Maggi and S. Romagnani. 1996. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. Faseb J. 10:769.
25. Del Prete G., M. De Carli, M.M. D'Elios, K.C. Daniel, F. Almerigogna, M. Alderson, C.A. Smith, E. Thomas and S. Romagnani. 1995. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J. Exp. Med. 182:1655.
26. D'Elios M. M., P. Romagnani, C. Scaletti, F. Annunziato, M. Manghetti, C. Mavilia, P. Parronchi, C. Pupilli, G. Pizzolo, E. Maggi, G.F. Del Prete and S. Romagnani. 1997. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J. Leukoc. Biol. 61:539.
27. Amedei A., C. Romagnani, M. Benagiano, A. Azzurri, F. Fomia, F. Torrente, A. Plebani, M.M. D'Elios and G. Del Prete. 2001. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur. J. Immunol. 31:1927.
28. Del Prete G., M. De Carli, F. Almerigogna, C.K. Daniel, M.M. D'Elios, G. Zancuoghi, F. Vinante, G. Pizzolo and S. Romagnani. 1995. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. Faseb J. 9:81.
29. Ellis T.M., P.E. Simms, D.J. Slivnick, H.M. Jack and R.I. Fisher. 1993. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151:2380.
30. Nakamura T., R.K. Lee, S.Y. Nam, B.K. Al-Ramadi, P.A. Koni, K. Bottomly, E.R. Podack and R.A. Flavell. 1997. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J. Immunol. 158:2090.
31. Gerli R., C. Lunardi, F. Vinante, O. Bistoni, G. Pizzolo and C. Pitzalis. 2001. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 22:72.
32. Triebel F. 2003. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol. 24:619.
33. Hannier S., M. Tournier, G. Bismuth and F. Triebel. 1998. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J. Immunol. 161:4058.
34. Avice M.N., M. Sarfati, F. Triebel, G. Delespesse and C.E. Demeure. 1999. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J. Immunol. 162:2748.
35. Carlo E.D., P. Cappello, C. Sorrentino, T. D'Antuono, A. Pellicciotta, M. Giovarelli, G. Forni, P. Musiani and F. Triebel. 2005. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J. Pathol. 205:82.
36. Salmaso S., P. Mastrantonio, S.G. Wassilak, M. Giuliano, A. Anemona, A. Giammanco, A.E. Tozzi, M.L. Ciofi degli Atti and D. Greco. 1998. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group. Vaccine 16:1270.
37. Lienhardt C., A. Azzurri, A. Amedei, K. Fielding, J. Sillah, O.Y. Sow, B. Bah, M. Benagiano, A. Diallo, R. Manetti, K. Manneh, P. Gustafson, S. Bennett, M.M. D'Elios, K. McAdam and G. Del Prete. 2002. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol. 32:1605.